# The Group That Lost Least Did Best

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-group-that-lost-least-did-best

> A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

## Key points

- Remission: 85.0% (lifestyle), 73.9% (semaglutide), 60.0% (surgery), in inverse order to weight lost.
- 53 people split three ways. The surgical group's 60% is six people out of ten.
- Not randomized. Participants chose after clinical assessment, so the women sent for surgery were likely heavier and metabolically sicker.
- The most robust row is weight regain between years one and two: 14.3% vs 55.6% vs 66.7%, though it still compares self-selected groups.
- This cannot show semaglutide is worse for cancer, in either direction.

In young women with endometrial cancer who want to preserve fertility, losing weight is part of the cancer treatment rather than a side project. A study compared three routes (surgery, semaglutide, and an intensive lifestyle program) and found the group that lost the *least* weight had the **highest** rate of complete tumor remission.[1] That is almost certainly not what it looks like, and the reasons are instructive.

## Why weight matters in this cancer

Endometrial cancer is strongly linked to excess weight, through estrogen produced in fat tissue. In younger women who want to keep the option of pregnancy, standard surgery removes that option, so fertility-sparing treatment uses hormonal therapy and aims to reverse the conditions that produced the cancer. Weight loss is part of the oncological plan.

*Fifty-three women followed for two years. Participants were assigned after assessment and shared decision-making, not randomized.[1]*

|   | Sleeve gastrectomy | Semaglutide | Lifestyle program |
| --- | --- | --- | --- |
| Number | **10** | **23** | **20** |
| BMI reduction at 1 year | **Largest** | 4.04 kg/m² less than surgery | 2.12 kg/m² less than surgery |
| Weight regain by 2 years | 66.7% | 55.6% | **14.3%** |
| **Complete tumor remission** | **60.0%** | 73.9% | **85.0%** |

> Ranked by weight lost, surgery came first. Ranked by tumor remission, it came last.

## Start with the denominators

> **Ten patients had surgery. Their 60.0% remission rate is six people out of ten.** One person moving between categories changes that figure by ten percentage points. The other groups are twenty and twenty-three, so their remission figures move by four or five points on a single reclassification.

That alone accounts for a large share of the apparent ordering. Before reaching for any explanation of why surgery underperformed, the first question is whether the difference exists at all, and 53 people split three ways cannot answer it.

## Then the way people ended up in each group

Participants were not randomized. They arrived at their treatment *after multidisciplinary assessment and shared decision-making*, which is exactly right as clinical practice and fatal to the comparison.

> **The women steered toward bariatric surgery are not the same women steered toward a lifestyle program.** They are likely heavier and likely to have more metabolic disease, because the authors say the team’s recommendation rested on BMI, metabolic disease and patient preference.[1] Either of those differences would independently predict a lower remission rate.

So the most economical explanation for the inverse ordering is not that losing weight surgically harms tumor response. It is that the sickest patients were sent for the most aggressive intervention, and their tumors behaved accordingly.

This is the same problem we have documented repeatedly in observational comparisons of these drugs: treatment assignment carrying information about the patient. The general case is in [when a hazard ratio is too good](https://glpwatchdog.org/research/when-a-hazard-ratio-is-too-good), and what a study can do to earn trust despite it is in [how to trust an observational study](https://glpwatchdog.org/research/how-to-trust-an-observational-study). This study does none of those things, and does not claim to.

## What to take from it anyway

One row holds up better than the others, though it still compares self-selected groups: **weight regain between the first and second year was 14.3% in the lifestyle group against 55.6% and 66.7%**, a difference the authors report as statistically significant.[1] It counts only the 29 women with complete two-year data, so each figure is a handful of people.

That fits everything else this register has documented about maintenance. The drug and the operation produce faster loss; keeping it requires something continuing. Two-thirds of the surgical patients with two-year data regaining in the second year is consistent with the wider evidence on [weight regain after bariatric surgery](https://glpwatchdog.org/research/glp1-after-bariatric-surgery-weight-regain), and the semaglutide figure fits a protocol that stopped the drug at least two months before any planned pregnancy.[1]

> **What this cannot support, and must not be read as, is that semaglutide is worse for cancer outcomes.** Fifty-three self-selected patients cannot establish that in either direction. The randomized evidence on cancer risk with these drugs is a separate and much stronger body of work (see [the randomized answer](https://glpwatchdog.org/research/glp1-cancer-risk-the-randomized-answer)).

## Frequently asked questions

### Does weight loss help fertility-sparing endometrial cancer treatment?

Weight loss is part of the treatment plan, because this cancer is driven partly by estrogen produced in fat tissue. This study is too small and too selected to establish which route to weight loss produces better tumor outcomes.

### The lifestyle group had the highest remission rate. Does that mean it is best?

Almost certainly not. Participants chose their treatment after clinical assessment rather than being randomized, so the women sent for surgery were likely heavier and metabolically sicker, both of which independently predict lower remission.

### How small is the study?

Fifty-three women in total: ten who had surgery, twenty-three on semaglutide and twenty in the lifestyle program. The surgical group's 60% remission rate is six people out of ten.

### Does this mean semaglutide is bad for cancer outcomes?

No, and it cannot support that in either direction. Randomized evidence on cancer risk with these drugs exists separately and is far stronger.

### Is anything in it reliable?

The weight regain figures hold up best: 14.3% regained weight between the first and second year in the lifestyle group, against 55.6% and 66.7%. That is consistent with everything else known about maintenance, though it still compares self-selected groups and counts only the 29 women with two years of data.

## References

1. Wei Y, Gong Y, Gong J, et al. Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study. Journal of Obstetrics and Gynaecology. 2026. PMID: 42495930. https://pubmed.ncbi.nlm.nih.gov/42495930/

---

Cite as: GLP Watchdog, Nora Bissett, "The Group That Lost Least Did Best", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/the-group-that-lost-least-did-best

Canonical HTML page: https://glpwatchdog.org/research/the-group-that-lost-least-did-best

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
